基于竞争情报的仿制药竞争力评价指标体系研究与应用  

Competitive Intelligence-based Research and Application on Competitiveness Evaluation Index System of Generic Drug

作　　者：文晓芬[1] 史敏[2] 廖婷[1] 刘召栋[1] 李维思[1] 胡锡晟[1] Wen Xiaofen;Shi Min;Liao Ting;Liu Zhaodong;Li Weisi;Hu Xisheng(Hunan Institute of Science and Technology Information,Changsha Hunan 410001;Business School,Hunan Agricultural University,Changsha Hunan 410128)

机构地区：[1]湖南省科学技术信息研究所,湖南长沙410001 [2]湖南农业大学商学院,湖南长沙410128

出　　处：《情报探索》2020年第12期44-49,共6页Information Research

基　　金：湖南省自然科学基金项目“基于竞争情报的生物医药产业新药立项品种选择评价体系研究”(项目编号:2019JJ50302);湖南省自然科学基金面上项目“基于新产品开发的企业创新能力提升服务体系研究及其应用”(项目编号:2018JJ2216)研究成果。

摘　　要：[目的/意义]旨在为生物医药企业降低新产品开发风险,提高新产品核心竞争力提供参考。[方法/过程]研究建立仿制药品种选择竞争力评价指标体系,并设计一套完整的仿制药品种筛选竞争情报服务方法,从药品药理情况、市场规模与预测、专利保护与技术壁垒、竞争格局、企业匹配度多个维度,开展药品竞争力评价。[结果/结论]该评价指标体系可以有效协助制药企业从海量药品选题中筛选、评价出具有竞争优势仿制药品种。[Purpose/significance]The paper is to reduce the risk of new product development and improve the core competitiveness of new products for biomedical enterprises in our province.[Method/process]The paper establishes an evaluation index system of the selection of drugs and design a complete set of competitive intelligence service methods for screening of generic drugs.Then it evaluates the competitiveness of drugs from aspects of pharmacologic action,market size and forecast,patent protection and technical barriers,product competition pattern,enterprise matching degree.[Result/conclusion]The evaluation index system is effectively usefull for pharmaceutical enterprises to select and evaluate generic drug development varieties with competitive advantages from a large number of drugs.

关 键 词：竞争情报 仿制药 品种选择 竞争力评价 

分 类 号：G350[文化科学—情报学]